Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis

Inflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their charact...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical microbiology 2016-09, Vol.65 (9), p.1038-1046
Hauptverfasser:	de Moreno de LeBlanc, Alejandra, Del Carmen, Silvina, Chatel, Jean-Marc, Azevedo, Vasco, Langella, Philippe, Bermudez-Humaran, Luis, LeBlanc, Jean Guy
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal Experimentation Animals Biological Therapy - methods Colitis - prevention & control Colitis - therapy Drug-Related Side Effects and Adverse Reactions Female Lactococcus lactis - genetics Lactococcus lactis - pathogenicity Life Sciences Mice, Inbred BALB C Probiotics - adverse effects Streptococcus thermophilus - genetics Streptococcus thermophilus - pathogenicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!